Relationship of plasma interleukin-6 and its genetic variants with hypertension in Hong Kong chinese by Ong, KL et al.
Title Relationship of plasma interleukin-6 and its genetic variants withhypertension in Hong Kong chinese
Author(s) Cheung, BMY; Ong, KL; Tso, AWK; Leung, RYH; Cherny, SS;Sham, PC; Thomas, GN; Lam, TH; Lam, KSL
Citation American Journal Of Hypertension, 2011, v. 24 n. 12, p. 1331-1337
Issued Date 2011
URL http://hdl.handle.net/10722/139444
Rights Creative Commons: Attribution 3.0 Hong Kong License
 1 
 
 
Word count:    224 (abstract)  2990 (text) 1 
No. of references: 40 2 
No. of tables: 4    No. of figures: 3 3 
Relationship of plasma interleukin-6 and its genetic variants with hypertension in Hong 4 
Kong Chinese 5 
Short title: IL-6 and hypertension 6 
 7 
Bernard MY Cheung
1,2
, Kwok Leung Ong
1
, Annette WK Tso
1,2
, Raymond YH Leung
1
, Stacey 8 
S Cherny
3,4
, Pak Chung Sham
3,4,5
, G Neil Thomas
6
, Tai Hing Lam
7
, Karen SL Lam
1,2
 on 9 
behalf of the Investigators of the Hong Kong Cardiovascular Risk Factor Prevalence Study 10 
 11 
1
Department of Medicine, 
2
Research Centre of Heart, Brain, Hormone and Healthy Aging, 12 
3
Department of Psychiatry, 
4
State Key Laboratory of Brain and Cognitive Sciences, and 13 
5
Genome Research Centre, The University of Hong Kong, Hong Kong; 
6
Department of
 14 
Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, UK; 15 
7
Department of Community Medicine and School of Public Health, The University of Hong 16 
Kong, Hong Kong 17 
 18 
Correspondence 19 
Prof Bernard MY Cheung, University Department of Medicine, Queen Mary Hospital, Hong 20 
Kong.  Tel: +852 22554347;  Fax: +852 28186474;  E-mail: mycheung@hku.hk 21 
 22 
Disclosure: The authors declared no conflict of interest. 23 
Keywords:  blood pressure; hypertension; interleukin-6; single nucleotide 24 
polymorphism25 
*Manuscript
 2 
 
 
Abstract 1 
 2 
BACKGROUND:  Interleukin-6 (IL-6) plays a central role in inflammation, insulin 3 
resistance, and atherogenesis.  We investigated the associations of plasma IL-6 and its 4 
genetic variants with hypertension in both cross-sectional and prospective study designs. 5 
METHODS:  Plasma IL-6 was measured in 648 normotensive and 294 hypertensive 6 
subjects from the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS)-2 7 
in 2000-2004 and three tagging SNPs in the IL-6 gene were genotyped.  Among 8 
subjects normotensive in CRISPS-2 (baseline), 515 subjects were followed up in 9 
CRISPS-3 in 2005-2008 and 100 of them had developed hypertension.   10 
RESULTS:  At baseline, plasma IL-6 correlated with systolic blood pressure (r=0.128, 11 
P<0.001).  Hypertensive subjects had significantly higher plasma IL-6 after adjusting 12 
for age and sex (geometric mean [95% CI] = 0.60 [0.54-0.65] vs 0.47 [0.44-0.50] ng/l, 13 
P=0.021).  In multiple logistic regression, higher plasma IL-6 was associated with 14 
hypertension in women (P=0.011), but not in men.  The SNP rs1800796 was associated 15 
with plasma IL-6 (β=-0.109, P=0.001).  However, this SNP was not associated with 16 
hypertension or blood pressure at baseline.  Among subjects normotensive in CRISPS-2, 17 
plasma IL-6 was not associated with the development of hypertension in CRISPS-3. 18 
CONCLUSION:  The SNP rs1800796 affected plasma IL-6 with a small effect size.  19 
Elevated plasma IL-6 is associated with prevalent hypertension in women, but not 20 
incident hypertension, suggesting that hypertension could be caused by other factors 21 
that might elevate plasma IL-6.  22 
 3 
 
 
Introduction 1 
Obesity is known to be associated with both inflammation and hypertension.  Excess adipose 2 
tissues can secrete proinflammatory cytokines, leading to insulin resistance and increased 3 
hepatic production of CRP.
1
  Interleukin-6 (IL-6) is a pro-inflammatory cytokine, which 4 
plays a central role in chronic inflammation, insulin resistance, and atherogenesis.
1
  One of 5 
the major sites for IL-6 secretion is visceral fat, which may explain the relationship between 6 
visceral fat and systemic inflammation in abdominally obese subjects.
2
  IL-6 also plays a 7 
regulatory role in hepatic production of C-reactive protein (CRP) and fibrinogen,
3
 which are 8 
often elevated in the plasma of hypertensive subjects.
4,5
  Plasma IL-6 is associated with 9 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) in apparently healthy men.
6
  10 
Some of the pro-atherosclerotic and pro-inflammatory effects of CRP are mediated partly by 11 
increased production of IL-6.
7
  Moreover, IL-6 can enhance myocyte hypertrophy and left 12 
ventricular remodelling.
8
  On the other hand, elevated blood pressure could also lead to 13 
vascular inflammation and hence elevated levels of inflammatory markers.
9
  Vasoactive 14 
peptides, such as angiotensin II, can also increase IL-6 expression leading to vascular 15 
inflammation.
10
  Therefore, whether plasma IL-6 can predict the development of 16 
hypertension is unclear.  Conventional cardiovascular risk factors such as age and HDL 17 
cholesterol are associated with both hypertension and plasma IL-6,
6,11
 which may thus 18 
confound the relationship between hypertension and plasma IL-6, leading to inconsistent 19 
findings in previous prospective studies, mainly in Caucasians.
11,12
 20 
 21 
There are some studies suggesting that genetic variants in the gene encoding IL-6 (IL6) may 22 
affect the risk of hypertension.
13-15
  We previously demonstrated that a single nucleotide 23 
polymorphism (SNP), rs1800796 (-572C>G), could influence plasma fibrinogen
16
 and 24 
fibrinogen may play a role in the development of hypertension in Hong Kong Chinese.
4
  25 
 4 
 
 
Previously, we studied the only SNP in the 940 bp fragment of the IL6 promoter present in 1 
our population, rs1800796, and found that it was not associated with hypertension.
16
 2 
However, the relationship of plasma IL-6 with this SNP and incident hypertension was 3 
unknown.  Moreover, there may be some other SNPs in IL6, located in exons, introns and the 4 
more upstream regions that may affect plasma IL-6 and modulate the risk of hypertension.  In 5 
the present study, we therefore investigated whether tagging SNPs in IL6 may influence 6 
plasma IL-6 and whether plasma IL-6 is related to hypertension and predicts its development.   7 
 8 
Methods 9 
Subjects 10 
The Hong Kong Cardiovascular Risk Factor Prevalence Study is a population-based 11 
prospective cohort study of cardiovascular risk factors in Hong Kong Chinese.
17,18
  In 1995-12 
1996 (CRISPS-1), a random sample of 2,895 Hong Kong Chinese subjects, representative of 13 
the general population, was recruited.  In 2000-2004, 1,944 subjects were followed up in 14 
CRISPS-2 and detailed reasons for non-participation have been described previously.
17,18
 15 
Among the 1,944 subjects from the CRISPS-2 cohort, plasma IL-6 was measured in 942 16 
subjects, 49.3% of whom were women who were randomly selected after stratification for 17 
sex.  The study protocol was approved by the Ethics Committee of the University of Hong 18 
Kong and the Institutional Review Board of the Hong Kong West Cluster of Hospitals.  19 
Written informed consent was obtained from all participants.   20 
 21 
SNPs selection 22 
Tagging SNPs in IL6 were selected from the HapMap Han Chinese (Phase II data, release 22).  23 
There were four tagging SNPs that captured all the 6 SNPs from 5kb region upstream to 2kb 24 
downstream of the gene (position 22,728,345-22,740,141, GenBank accession number 25 
 5 
 
 
NC_000007) with r
2≥0.9 and minor allele frequency (MAF) ≥0.05 (Figure 1 & 1 
Supplementary Table S1).  Genotyping was performed using the MassARRAY system 2 
(Sequenom, San Diego, CA) with the iPLEX
TM
 assay.  After genotyping, the SNP rs2069852 3 
showed significant deviation from Hardy-Weinberg equilibrium (HWE) among all subjects 4 
(P=0.002) and normotensive subjects (P=0.017), and was excluded from analysis.  The 5 
remaining three SNPs captured 5 (83.3%) out of 6 genotyped SNPs in the HapMap Han 6 
Chinese. 7 
 8 
Variables of interest 9 
Hypertension was defined as blood pressure ≥140/90 mm Hg, or taking anti-hypertensive 10 
medication.  Blood pressure was measured in a sitting position three times at 5-minute 11 
intervals using an appropriately sized cuff and a mercury sphygmomanometer by a trained 12 
nurse after the subjects had sat for ≥10 minutes as described previously.17,18  Venous blood 13 
was taken from a forearm in the morning after overnight fasting for routine clinical 14 
biochemical assays and plasma samples were stored at -70°C until the time of assay.  Plasma 15 
IL-6 was measured in duplicate using high-sensitivity enzyme-linked immunosorbent assay 16 
(ELISA) kits (Bender MedSystems GmbH, Vienna, Austria).  The kit had a sensitivity of 17 
0.02 pg/ml, intra-assay coefficient of variation of 6.9% and inter-assay coefficient of 18 
variation of 8.0%.  Plasma high-sensitivity CRP and adiponectin were measured as described 19 
previously.
19
  Details on the measurement of other clinical parameters such as fasting glucose, 20 
2-h glucose after oral glucose tolerance test, fasting insulin, homeostasis model assessment of 21 
insulin resistance index (HOMA-IR), triglycerides, low-density lipoprotein (LDL) cholesterol, 22 
high-density lipoprotein (HDL) cholesterol, and fibrinogen had been described previously.
16-23 
19
  Data on alcohol drinking, smoking, and history of hypertension were obtained by 24 
 6 
 
 
standardized interviewing using a questionnaire.  Regular drinking was defined as 1 
consumption of alcoholic drinks at least once a week.  2 
 3 
Statistical analysis 4 
Subject characteristics were compared using SPSS 15.0 (SPSS Inc., Chicago, IL).  Variables 5 
with skewed distribution, such as triglycerides, fasting glucose, 2-h glucose, fasting insulin, 6 
HOMA-IR, plasma adiponectin, CRP, and IL-6, were log-transformed before analysis.  7 
Variables were used as covariates in the multiple regression analysis if they were likely to 8 
affect the risks of hypertension, or correlated with plasma IL-6.  For variables that were 9 
highly correlated such as body mass index (BMI) and waist circumference, only one was 10 
entered into the regression model.  Haploview (version 4.1) was used to estimate pairwise 11 
linkage disequilibrium (LD) and select the tagging SNPs.
20
  Single variant analysis was 12 
performed under the assumption of a dominant model of inheritance for the minor allele as 13 
there were few subjects who were homozygous for the minor alleles.  Using Genetic Power 14 
Calculator
21
, our study of 294 hypertensive subjects and 648 normotensive subjects had 80% 15 
power to detect an odds ratio (OR) of 1.53 for an allele frequency of 0.15 at the 5% 16 
significance level in a dominant inheritance model, assuming a disease prevalence of 31.2%.  17 
Correction for multiple testing of three SNPs was performed by the SNP spectral 18 
decomposition method (SNPSpD).
22
  Under this method, the effective number of independent 19 
marker loci (MeffLi) was 2 and the experimental-wide significance threshold to keep type 1 20 
error rate at 5% was 0.0253.  Correction for testing of multiple phenotypes was not 21 
performed as the phenotypes tested were closely related to each other.   22 
 23 
Results 24 
Clinical characteristics and genotyping 25 
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Among 1,944 subjects in CRISPS-2, plasma IL-6 was measured in 942 subjects, who were 1 
randomly selected after stratification for sex, 49.3% of whom were women.  There was no 2 
significant difference in age between those with (n=942) and without (n=1,002) plasma IL-6 3 
measurement among all subjects, men, or women.  There was no significant difference in 4 
waist circumference, triglycerides, fasting glucose, 2-h glucose, fasting insulin, HOMA-IR, 5 
fibrinogen, and proportion of regular drinking between those with and without plasma IL-6 6 
measurement after adjusting for sex.  However, subjects with plasma IL-6 measurement had 7 
lower BMI, LDL cholesterol and CRP, but higher HDL cholesterol, adiponectin, and 8 
prevalence of smoking and hypertension after adjusting for sex (all P<0.05).  Table 1 shows 9 
the baseline clinical characteristics of the 294 hypertensive and 648 normotensive subjects in 10 
CRISPS-2.  Supplementary Table S2 shows the baseline clinical characteristics of the 11 
subjects by sex.  Women had significantly lower BMI, waist circumference, SBP, DBP, 12 
triglycerides, and fasting glucose, but higher HDL cholesterol, fibrinogen, and plasma 13 
adiponectin.  Women also had much lower proportions of current smoking and regular 14 
drinking than men.  15 
 16 
The three SNPs, rs17147230, rs1800796, and rs2069837, were all genotyped successfully in 17 
≥99.9% of the subjects with MAFs of 0.430, 0.207, and 0.158 respectively.  These SNPs did 18 
not show significant deviation from HWE among all subjects or among case- and control-19 
specific subgroups (P>0.08).  The pairwise LD (r
2
) between rs17147230 and rs1800796, 20 
rs1800796 and rs2069837, and rs17147230 and rs2069837 were 0.166, 0.680, and 0.093 21 
respectively.   22 
 23 
Association of plasma IL-6 with hypertension at baseline 24 
 8 
 
 
At baseline, plasma IL-6 correlated with age (r=0.174, P<0.001), BMI (r=0.121, P<0.001), 1 
waist circumference (r=0.123, P<0.001), SBP (r=0.128, P<0.001), log-transformed 2 
triglycerides (r=0.077, P=0.019), HDL cholesterol (r=-0.100, P=0.002), log-transformed 3 
CRP (r=0.254, P<0.001), and fibrinogen (r=0.236, P<0.001).  The correlation of plasma IL-6 4 
with SBP remained significant after excluding subjects on anti-hypertensive medication 5 
(r=0.083, P=0.020) or when blood pressures in treated subjects were adjusted by adding 10/5 6 
mm Hg (r=0.140, P<0.001).
23
  Figure 2 shows the mean SBP according to plasma IL-6 7 
tertiles.  Plasma IL-6 did not differ significantly between subjects who were or were not 8 
current smokers (geometric mean [95% CI] = 0.54 [0.48-0.61] vs 0.49 [0.47-0.53] ng/l, 9 
P=0.192).  It was not related to other clinical characteristics shown in Table 1 (all P≥0.05).  10 
Among hypertensive subjects, plasma IL-6 did not differ between subjects with (n=170) and 11 
without (n=124) anti-hypertensive medication (P=0.120 after adjusting for age and sex). 12 
 13 
As shown in Table 1, plasma IL-6 was higher in hypertensive subjects at baseline (P=0.021).  14 
In an unadjusted model, the association of plasma IL-6 with hypertension was significant in 15 
women (P<0.001), but not in men (P=0.466) in sex-specific analysis (P for 16 
interaction=0.001).  In multiple logistic regression analysis, higher plasma IL-6 was 17 
independently associated with hypertension in women only (Table 2).  The sex-interaction in 18 
the association of plasma IL-6 with hypertension remained significant after adjusting for the 19 
main effects of all the covariates (P=0.010).   No significant interaction between plasma IL-6 20 
and other covariates was found in the full adjustment model.  Similar results were obtained if 21 
BMI was replaced by waist circumference in the regression model (data not shown) or if BMI 22 
was removed from the model (P=0.627 and 0.003 in men and women for IL-6 respectively). 23 
 24 
Association of SNPs with plasma IL-6 at baseline 25 
 9 
 
 
As shown in Figure 3, the SNP rs1800796 was significantly associated with plasma IL-6 at 1 
baseline after adjusting for age and sex (β=-0.090, P=0.005).  The presence of the minor G 2 
allele was associated with a plasma IL-6 level 14.6 (95% CI: 4.6-23.5)% lower.  In multiple 3 
linear regression analysis, rs1800796 was independently associated with plasma IL-6 (Table 4 
3).  There was no significant sex-interaction after adjusting for the main effects of all the 5 
covariates (P=0.427).  Similar results were obtained if BMI was replaced by waist 6 
circumference or was removed in the regression model (P=0.001 for rs1800796 in both cases).  7 
Among the clinical characteristics shown in Table 1, the presence of the minor G allele of 8 
rs1800796 was also associated with higher plasma fibrinogen (mean±SD: 3.08±0.61 g/l for 9 
CG+GG vs 2.94±0.60 g/l for CC) after adjusting for age, sex, and plasma IL-6 (P<0.001), but 10 
not other characteristics. 11 
 12 
Association of SNPs with hypertension at baseline 13 
None of the SNPs were significantly associated with hypertension at baseline (P>0.05, 14 
Supplementary Table 3).  Among subjects not taking anti-hypertensive medication, none of 15 
the SNPs were significantly associated with SBP or DBP at baseline (P>0.05, Supplementary 16 
Table S3).  Similar insignificant results were obtained when blood pressures in treated 17 
subjects were adjusted by adding 10/5 mmHg (data not shown).
23
  Sex-specific analysis also 18 
did not reveal a significant association of SNPs with prevalent hypertension, SBP or DBP 19 
(P>0.05, Supplementary Table S3). 20 
 21 
Follow-up study in CRISPS-3 22 
Among 648 subjects normotensive in CRISPS-2, 515 subjects were followed up in CRISPS-3 23 
in 2005-2008 after a median interval of five years and 100 of them had developed 24 
hypertension in CRISPS-3 (Table 4).  Baseline plasma IL-6 did not differ significantly 25 
 10 
 
 
between subjects with or without incident hypertension.  Sex-specific analysis also did not 1 
reveal a significant difference.  Among 294 subjects hypertensive in CRISPS-2, 213 subjects 2 
were followed up in CRISPS-3 and 189 subjects remained hypertensive in CRISPS-3.  3 
Among 415 subjects normotensive at both visits and 189 subjects hypertensive at both visits, 4 
plasma IL-6 level was higher in hypertensive subjects, especially in women.  Supplementary 5 
Table S4 shows the baseline characteristics of these subjects.  However, none of the SNPs 6 
were significantly associated with hypertension or blood pressure (both adjusting for and 7 
removing those taking anti-hypertensive medication) among subjects who were either 8 
normotensive or hypertensive at both CRISPS-2 and CRISPS-3 (data not shown). 9 
 10 
Discussion 11 
Elevated plasma levels of inflammatory markers are often associated with cardiovascular 12 
diseases and mortality in prospective studies.
8,24,25
  In some studies, the association is even 13 
stronger for plasma IL-6 than other inflammatory markers such as CRP and tumor necrosis 14 
factor (TNF)-α.8,25   As hypertension is a risk factor for cardiovascular diseases and mortality, 15 
plasma IL-6 may also be associated with hypertension or blood pressure.  The association of 16 
plasma IL-6 with blood pressure and prevalent hypertension in our cross-sectional study 17 
supports the concept of chronic inflammation in hypertension.
4-6,11,12
  The association tended 18 
to be stronger in women with significant sex-interaction.  This is consistent with the higher 19 
prevalence of cardiovascular risk factors in women with hypertension.
26
  This gender 20 
difference is also observed in other inflammatory markers, such as fibrinogen.
4
  In this study 21 
sample, the proportion of current smoking was much higher in men than women.  22 
Interestingly, smoking could interact with genetic variants in IL6 on the circulating levels of 23 
inflammatory markers.
27
  This may contribute partly to the difference in the association of 24 
 11 
 
 
plasma IL-6 with hypertension and the strikingly different OR for the association of smoking 1 
with hypertension between men and women. 2 
  3 
In fact, there are two prospective studies on the role of IL-6 in the prediction of the 4 
development of hypertension,
11,12
 but their findings are inconsistent.  In the Women's Health 5 
Study, the association of plasma IL-6 with incident hypertension was no longer significant 6 
after further adjusting for conventional cardiovascular risk factors and plasma CRP.
11
  In the 7 
Multi-Ethnic Study of Atherosclerosis (MESA), plasma IL-6 was significantly associated 8 
with incident hypertension even after adjusting for conventional cardiovascular risk factors.
12
  9 
However, compared to the Women's Health Study, plasma CRP was not used as a covariate 10 
in the adjustment model in the MESA study.  In our study, baseline plasma IL-6 did not differ 11 
significantly between subjects with or without new-onset hypertension at follow-up in a 12 
simple model after adjusting for age, sex, and follow-up duration.  Therefore, our study 13 
supports the findings from the Women's Health Study that plasma IL-6 could not predict the 14 
future risk of hypertension and hypertension may be caused by other factors that elevate 15 
plasma IL-6.  In the Copenhagen City Heart Study, plasma CRP and fibrinogen, acute phase 16 
proteins downstream of IL-6 in the inflammatory cascade and markers of chronic 17 
inflammation, were not associated with blood pressure.
28
   18 
 19 
As hypertension is a complex disease and environmental factors also play an important role 20 
in its development, we studied the association of genetic variants with hypertension or blood 21 
pressure related traits, which were less likely to be confounded by environmental factors.  22 
The SNP rs1800796, which was significantly associated with plasma IL-6, was not associated 23 
with hypertension or blood pressures in our study.  This may be due to its small effect size on 24 
plasma IL-6.  Nevertheless, together with the negative association of plasma IL-6 with 25 
 12 
 
 
incident hypertension, our finding also does not support a major direct role of IL-6 in the 1 
development of hypertension. 2 
 3 
The SNP rs1800796 possesses functional effects in the luciferase reporter gene assay.
29
  In 4 
our study, the minor G allele of rs1800796 was significantly associated with lower plasma 5 
IL-6 but higher plasma fibrinogen.  It may seem contradictory as both elevated plasma IL-6 6 
and fibrinogen are associated with higher risks of hypertension
4,6,11,12
 and cardiovascular 7 
adverse events.
8,24,25
  In fact, endogenous IL-6 also has anti-inflammatory properties in the 8 
regulation of pro-inflammatory cytokines, such as TNF-α and IL-1β, in both local and 9 
systemic acute inflammatory responses.
30
  Similarly, a genetic variant, rs8192284, in the IL-6 10 
receptor gene (IL6R) is associated with lower plasma IL-6, but higher risk for the metabolic 11 
syndrome in Southern Chinese.
31
  It is interesting that the G allele of rs1800796 was 12 
associated with lower plasma IL-6 in our and other studies,
32,33
 but higher plasma IL-6 in 13 
some other studies.
34,35
  Nevertheless, this discrepancy in the allelic effect on plasma IL-6 in 14 
the literature does not detract from the final conclusion of the present study regarding the 15 
association of a genetic variant in IL6 with its plasma level.   16 
 17 
In this study, genetic variants in IL6 are not associated with hypertension or any blood 18 
pressure related traits.  This is consistent with our previous case-control study in Hong Kong 19 
Chinese, showing no significant association of rs1800796 with hypertension.
16
  Similarly, 20 
rs1800795 in IL6 was not associated with incident hypertension in a prospective cohort of 21 
Caucasian women.
36
   In fact, genetic variants in IL6 have been shown to be associated with 22 
type 2 diabetes,
35,37
 ischemic stroke,
38
 and coronary heart disease.
13,39
 Therefore, IL-6 may be 23 
more related to these diseases than hypertension.  The elevated plasma IL-6 in hypertension 24 
 13 
 
 
may be partly due to the presence of these closely related diseases or their underlying risk 1 
factors. 2 
 3 
Our study has the advantages of investigating the relationship between IL-6 and hypertension 4 
using both cross-sectional and prospective study designs as well as genotype data.  However, 5 
the major limitation of this study is the small sample size, which limits the power to identify 6 
the risk factors of incident hypertension and detect small effect size of genetic variants that 7 
are usually encountered in recent genome-wide association studies of hypertension.
40
  The 8 
association of SNPs with blood pressure and that of plasma IL-6 with incident hypertension 9 
may become significant if a larger cohort study were used.  As subjects were recruited from 10 
the general population, hypertensive subjects were older than normotensive subjects.  There 11 
was also a high percentage of anti-hypertensive medication treatment among hypertensive 12 
subjects (57.8%) in our population-based cohort although plasma IL-6 was not related to anti-13 
hypertensive medication treatment.  Moreover, as hypertension is a polygenic disease, our 14 
study only investigated SNPs in IL6, but not those in genes encoding other inflammatory 15 
markers, which may interact with SNPs in IL6.  The single measurement of plasma IL-6 may 16 
not be sufficient to reflect chronic IL-6 level and inflammation status. 17 
 18 
In conclusion, plasma IL-6 is elevated in hypertension, but cannot predict incident 19 
hypertension.  Although plasma IL-6 is affected by the SNP rs1800796, this SNP is not 20 
associated with hypertension or blood pressure, suggesting that hypertension is caused by 21 
other factors that elevate plasma IL-6.   22 
 23 
Acknowledgement 24 
 14 
 
 
This study was funded by Hong Kong Research Grants Council grants (HKU7229/01M and 1 
HKU7626/07M) and the Sun Chieh Yeh Heart Foundation. 2 
 3 
Disclosure 4 
The authors declared no conflict of interest. 5 
 6 
References 7 
1. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular 8 
inflammatory syndrome. Endocr Rev 2003;24:278-301. 9 
2. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion 10 
is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010-1013. 11 
3. Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, 12 
Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in 13 
adult human hepatocytes. FEBS Lett 1989;242:237-239.  14 
4. Ong KL, Tso AW, Cherny SS, Sham PC, Lam KS, Jiang CQ, Thomas GN, Lam TH, 15 
Cheung BM. A genetic variant in the gene encoding fibrinogen beta chain predicted 16 
development of hypertension in Chinese men. Thromb Haemost 2010;103:728-735.  17 
5. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein 18 
and the risk of developing hypertension. JAMA 2003;290:2945-2951. 19 
6. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently 20 
healthy men. Hypertension 2001;38:399-403. 21 
7. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. 22 
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects 23 
of C-reactive protein. Circulation 2002;105:1890-1896. 24 
8. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer 25 
 15 
 
 
DB, Levy D, Wilson PW, D'Agostino RB; Framingham Heart Study. Inflammatory 1 
markers and risk of heart failure in elderly subjects without prior myocardial infarction: 2 
the Framingham Heart Study. Circulation 2003;107:1486-1491. 3 
9. Virdis A, Ghiadoni L, Plantinga Y, Taddei S, Salvetti A. C-reactive protein and 4 
hypertension: is there a causal relationship? Curr Pharm Des 2007;13:1693-1698. 5 
10. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, 6 
Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin 6 in 7 
human coronary atherosclerotic plaques: potential implications for inflammation and 8 
plaque instability. Circulation 2000;101:1372-1378. 9 
11. Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of interleukin-6 10 
and C-reactive protein for the risk of developing hypertension in women. Hypertension 11 
2007;49:304-310. 12 
12. Lakoski SG, Cushman M, Siscovick DS, Blumenthal RS, Palmas W, Burke G, 13 
Herrington DM. The relationship between inflammation, obesity and risk for 14 
hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens 15 
2011;25:73-79. 16 
13. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C 17 
promoter polymorphism is associated with risk of coronary heart disease and systolic 18 
blood pressure in healthy men. Eur Heart J 2001;22:2243-2252. 19 
14. Tanaka C, Mannami T, Kamide K, Takiuchi S, Kokubo Y, Katsuya T, Kawano Y, 20 
Miyata T, Ogihara T, Tomoike H. Single nucleotide polymorphisms in the interleukin-6 21 
gene associated with blood pressure and atherosclerosis in a Japanese general population. 22 
Hypertens Res 2005;28:35-41. 23 
15. Nakajima T, Ota N, Yoshida H, Watanabe S, Suzuki T, Emi M. Allelic variants in the 24 
interleukin-6 gene and essential hypertension in Japanese women. Genes Immun 25 
 16 
 
 
1999;1:115-119. 1 
16. Wong LY, Leung RY, Ong KL, Cheung BM. Plasma levels of fibrinogen and C-reactive 2 
protein are related to interleukin-6 gene -572C>G polymorphism in subjects with and 3 
without hypertension. J Hum Hypertens 2007;21:875-882.  4 
17. Cheung BM, Wat NM, Man YB, Tam S, Thomas GN, Leung GM, Cheng CH, Woo J, 5 
Janus ED, Lau CP, Lam TH, Lam KS. Development of diabetes in Chinese with the 6 
metabolic syndrome: a 6-year prospective study. Diabetes Care 2007;30:1430-1436. 7 
18. Cheung BM, Wat NM, Man YB, Tam S, Cheng CH, Leung GM, Woo J, Janus ED, Lau 8 
CP, Lam TH, Lam KS. Relationship between the metabolic syndrome and the 9 
development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence 10 
Study-2 (CRISPS2). Am J Hypertens 2008;21:17-22. 11 
19. Ong KL, Li M, Tso AW, Xu A, Cherny SS, Sham PC, Tse HF, Lam TH, Cheung BM, 12 
Lam KS; Investigators of the Hong Kong Cardiovascular Risk Factor Prevalence Study. 13 
Association of genetic variants in the adiponectin gene with adiponectin level and 14 
hypertension in Hong Kong Chinese. Eur J Endocrinol 2010;163:251-7. 15 
20. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and 16 
haplotype maps. Bioinformatics 2005;21:263-265. 17 
21. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and 18 
association genetic mapping studies of complex traits. Bioinformatics 2003;19:149-50 19 
22. Nyholt DR. A simple correction for multiple testing for single-nucleotide 20 
polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 21 
2004;74:765-769. 22 
23. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial 23 
contributions to blood pressure variation. Hypertension 2003;41:207-210. 24 
24. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 25 
 17 
 
 
and mortality in patients with unstable coronary artery disease: effects of an early 1 
invasive or noninvasive strategy. JAMA 2001;286:2107-2113. 2 
25. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, 3 
Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and 4 
onset of cardiovascular events: results from the Health ABC study. Circulation 5 
2003;108:2317-2322. 6 
26. Ong KL, Tso AW, Lam KS, Cheung BM. Gender difference in blood pressure control 7 
and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension 8 
2008;51:1142-1148. 9 
27. Sunyer J, Forastiere F, Pekkanen J, Plana E, Kolz M, Pistelli R, Jacquemin B, Brüske-10 
Hohlfeld I, Pitsavos Ch, Bellander T, Koenig W, Peters A; AIRGENE Study Group. 11 
Interaction between smoking and the interleukin-6 gene affects systemic levels of 12 
inflammatory biomarkers. Nicotine Tob Res 2009;11:1347-1353. 13 
28. Asferg C, Jensen JS, Marott JL, Appleyard M, Møgelvang R, Jensen GB, Jeppesen J. 14 
Markers of inflammation and hemodynamic measurements in obesity: Copenhagen City 15 
Heart Study. Am J Hypertens 2009;22:451-456. 16 
29. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter 17 
polymorphisms regulating interleukin-6 gene expression are associated with circulating 18 
levels of C-reactive protein and markers of bone resorption in postmenopausal women. J 19 
Clin Endocrinol Metab 2003;88:255-259. 20 
30. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. IL-6 is an 21 
antiinflammatory cytokine required for controlling local or systemic acute inflammatory 22 
responses. J Clin Invest 1998;101:311-320. 23 
31. Jiang CQ, Lam TH, Liu B, Lin JM, Yue XJ, Jin YL, Cheung BM, Thomas GN. 24 
Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the 25 
 18 
 
 
metabolic syndrome: GBCS-CVD. Obesity (Silver Spring) 2010;18:1969-1974.  1 
32. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, 2 
Humphries SE. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are 3 
strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. 4 
Arterioscler Thromb Vasc Biol 2001;21:1458-1463. 5 
33. Mälarstig A, Wallentin L, Siegbahn A. Genetic variation in the interleukin-6 gene in 6 
relation to risk and outcomes in acute coronary syndrome. Thromb Res 2007;119:467-7 
473. 8 
34. Sanderson SC, Kumari M, Brunner EJ, Miller MA, Rumley A, Lowe GD, Marmot MG, 9 
Humphries SE. Association between IL6 gene variants -174G>C and -572G>C and 10 
serum IL-6 levels: interactions with social position in the Whitehall II cohort. 11 
Atherosclerosis 2009;204:459-64. 12 
35. Koh SJ, Jang Y, Hyun YJ, Park JY, Song YD, Shin KK, Chae JS, Kim BK, Ordovas JM, 13 
Lee JH. Interleukin-6 (IL-6) -572C-->G promoter polymorphism is associated with type 14 
2 diabetes risk in Koreans. Clin Endocrinol (Oxf) 2009;70:238-244. 15 
36. Conen D, Cheng S, Steiner LL, Buring JE, Ridker PM, Zee RY. Association of 77 16 
polymorphisms in 52 candidate genes with blood pressure progression and incident 17 
hypertension: the Women's Genome Health Study. J Hypertens 2009;27:476-483. 18 
37. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK, Langer B, Thorand B, 19 
Klopp N, Hamid YH, Pedersen O, Hansen T, Lyssenko V, Groop L, Meisinger C, 20 
Döring A, Löwel H, Lieb W, Hengstenberg C, Rathmann W, Martin S, Stephens JW, 21 
Ireland H, Mather H, Miller GJ, Stringham HM, Boehnke M, Tuomilehto J, Boeing H, 22 
Möhlig M, Spranger J, Pfeiffer A, Wernstedt I, Niklason A, López-Bermejo A, 23 
Fernández-Real JM, Hanson RL, Gallart L, Vendrell J, Tsiavou A, Hatziagelaki E, 24 
Humphries SE, Wichmann HE, Herder C, Illig T. IL6 gene promoter polymorphisms 25 
 19 
 
 
and type 2 diabetes: joint analysis of individual participants' data from 21 studies. 1 
Diabetes 2006;55:2915-2921. 2 
38. Tong Y, Wang Z, Geng Y, Liu J, Zhang R, Lin Q, Li X, Huang D, Gao S, Hu D, Li Y, 3 
Cheng J, Lu Z. The association of functional polymorphisms of IL-6 gene promoter with 4 
ischemic stroke: analysis in two Chinese populations. Biochem Biophys Res Commun 5 
2010;391:481-485. 6 
39. Basso F, Lowe GD, Rumley A, McMahon AD, Humphries SE. Interleukin-6 -174G>C 7 
polymorphism and risk of coronary heart disease in West of Scotland coronary 8 
prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002;22:599-604. 9 
40. Delles C, McBride MW, Graham D, Padmanabhan S, Dominiczak AF. Genetics of 10 
hypertension: from experimental animals to humans. Biochim Biophys Acta 11 
2010;1802:1299-1308. 12 
13 
 20 
 
 
Figure legend 1 
 2 
Figure 1 A schematic diagram of IL6.  Exons and introns are represented by boxes and 3 
thin lines respectively with their sizes indicated above.  The MAFs of the tagging SNPs in 4 
HapMap Han Chinese are indicated in the brackets. 5 
 6 
Figure 2 Mean SBP in subjects according to the sex-specific plasma IL-6 tertiles at 7 
baseline.  For all subjects, blood pressures in treated subjects were adjusted by adding 10/5 8 
mm Hg.
17
  Error bars indicate standard errors.  The cut-off values of tertiles 1, 2 and 3 in men 9 
and women respectively are <0.438 ng/l and <0.380 ng/l, 0.438-0.763 ng/l and 0.380-0.683 10 
ng/l, and ≥0.764 ng/l and ≥0.784 ng/l. 11 
 12 
Figure 3 Association of SNPs with plasma IL-6 at baseline.  Error bars indicate 13 
standard errors of geometric means.  Subjects homozygous for the minor allele were grouped 14 
with heterozygotes for comparison with those homozygous for the major allele to increase the 15 
sample size, and P values were adjusted for age and sex. *P values that can pass multiple 16 
testing correction (P<0.0253). 17 
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Table 1  Clinical characteristics of 942 subjects in CRISPS-2 (baseline) 1 
Characteristics Normotensive (n=648) Hypertensive (n=294) 
Age (years) 49.9 ± 11.0 59.2 ± 10.7‡ 
Women (%) 50.5 46.6 
BMI (kg/m
2
) 23.3 ± 3.2 25.2 ± 3.3‡ 
Waist circumference (cm) 78.0 ± 9.7 84.7 ± 9.1‡ 
SBP (mm Hg)
b
 115.2 ± 11.3 147.4 ± 14.5‡ 
DBP (mm Hg)
b
 72.8 ± 8.2 89.3 ± 10.5‡ 
Triglyceride (mmol/l)
a
 1.11 (1.07-1.16) 1.49 (1.41-1.58)‡ 
HDL cholesterol (mmol/l) 1.40 ± 0.36 1.27 ± 0.37‡ 
LDL cholesterol (mmol/l) 3.17 ± 0.78 3.34 ± 0.89* 
Fasting glucose (mmol/l)
a
 5.13 (5.06-5.20) 5.78 (5.62-5.95)‡ 
2-h glucose (mmol/l)
a
 6.50 (6.32-6.69) 8.10 (7.72-8.50)‡ 
Fasting insulin (mIU/l)
a
 6.67 (6.40-6.95) 9.27 (8.66-9.93)‡ 
HOMA-IR
a
 1.52 (1.45-1.59) 2.38 (2.20-2.58)‡ 
Fibrinogen (g/l) 2.92 ± 0.58 3.15 ± 0.65† 
Adiponectin (mg/l)
a
 7.28 (6.93-7.64) 6.37 (5.91-6.86)‡ 
CRP (mg/l)
a
 0.54 (0.50-0.58) 0.88 (0.79-0.98)‡ 
IL-6 (ng/l)
a
 0.47 (0.44-0.50) 0.60 (0.54-0.65)* 
men 0.52 (0.48-0.57) 0.55 (0.48-0.63) 
women 0.42 (0.38-0.46) 0.65 (0.58-0.73)‡ 
Current smoking (%) 22.4 14.6‡ 
Regular drinking (%) 12.2 9.0* 
Data are expressed as meanSD unless otherwise stated.  2 
*P<0.05, †P<0.01, and ‡P<0.001 for normotensive versus hypertensive subjects after 3 
adjusting for age and sex, except for age (adjusted for sex only), sex (for age only) and sex-4 
specific IL-6 level (for age only).  5 
a
Data are expressed as geometric mean (95% CI) due to skewed distributions. 6 
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b
Subjects on anti-hypertensive medication were excluded (n=170).     1 
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Table 2  Multiple logistic regression analysis for hypertension at baseline 1 
Parameters Men (n=416) Women (n=415) 
 OR (95% CI) P  OR (95% CI) P  
Age (years) 1.07 (1.04-1.09) <0.001* 1.08 (1.05-1.11) <0.001* 
BMI (kg/m
2
) 1.12 (1.02-1.23) 0.017* 1.11 (1.01-1.21) 0.024* 
2-h glucose 
(mmol/l)
a
 
1.41 (1.08-1.84) 0.011* 0.90 (0.65-1.23) 0.501 
HOMA-IR
a
 1.04 (0.72-1.52) 0.827 1.70 (1.18-2.46) 0.004* 
Current smoking 0.48 (0.28-0.83) 0.008* 3.00 (0.88-10.29) 0.080 
IL-6 (ng/l)
a 
 0.92 (0.72-1.18) 0.517 1.49 (1.10-2.00) 0.009* 
Nagelkerke r
2
 0.299  0.358  
Triglycerides (log-transformed), HDL cholesterol, adiponectin (log-transformed), and regular 2 
drinking were also included in the model but they were not significant factors in all subjects, 3 
men or women (P>0.05). 4 
a
ORs are expressed in term of per SD of log-transformed unit. 5 
*P<0.05. 6 
7 
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Table 3  Multiple linear regression analysis for plasma IL-6 (log-transformed) at baseline 1 
(n=925) 2 
Parameters β P  
Age (years) 0.099 0.007* 
CRP (mg/l, log-transformed) 0.161 <0.001* 
Fibrinogen (g/l) 0.158 <0.001* 
Presence of minor G allele of rs1800796 -0.108 0.001* 
r
2
 0.103  
Sex, BMI, triglycerides (log-transformed), SBP, and HDL cholesterol were also included in 3 
the model but they were not significant factors (P>0.05). 4 
*P<0.05.5 
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Table 4  Baseline characteristics of 515 normotensive subjects in CRISPS-2 according to the 1 
hypertension status in CRISPS-3 2 
Characteristics Normotensive 
(n=415) 
Hypertensive 
(n=100) 
P
b
 
Age (years) 47.0 ± 9.6 55.7 ± 9.5 <0.001 
Women (%) 52.3 46.0 0.487 
BMI (kg/m
2
) 23.0 ± 2.9 24.1 ± 3.8 0.002 
SBP (mm Hg) 112.4 ± 10.2 124.8 ± 8.7 <0.001 
DBP (mm Hg) 71.9 ± 8.1 77.0 ±7.4 <0.001 
IL-6 (ng/l)
a
 0.44 (0.41-0.48) 0.51 (0.45-0.59) 0.355 
men 0.49 (0.44-0.56) 0.56 (0.47-0.67) 0.624 
women 0.40 (0.36-0.46) 0.46 (0.37-0.57) 0.401 
Data are expressed as meanSD or geometric mean (95% CI) unless otherwise stated.  3 
a
Data are expressed as geometric mean (95% CI) due to skewed distributions. 4 
b
Adjusted for baseline age, sex, and follow-up duration.  5 
  6 
 7 
 8 
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Supplementary Table S1  Tagging SNP selection 1 
SNP Chromosome 
position 
(NC_000007) 
Location in 
gene 
MAF 
(CHB 
HapMap) 
Alleles 
(Major : 
Minor) 
Tagging 
SNP 
r
2
 
rs17147230 22728701 5' near gene 0.378 A:T rs17147230 1.00 
rs1800796 22732771 5' near gene 0.233 C:G rs1800796 1.00 
rs2069837 22734552 intron 2 0.2 A:G rs2069837 1.00 
rs1524107 22734744 intron 2 0.25 T:C rs1800796 0.94 
rs2066992 22734774 intron 2 0.244 T:G rs1800796 0.94 
rs2069852 22738785 3' near gene 0.267 A:G rs2069852 1.00 
2 
Supplementary Tables
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Supplementary Table S2  Clinical characteristics of 942 subjects in CRISPS-2 (baseline) by 1 
sex 2 
Characteristics Men (n=478) Women (n=464) 
Age (years) 53.3 ± 12.0 52.3 ± 11.5 
BMI (kg/m
2
) 24.2 ± 3.3 23.5 ± 3.3† 
Waist circumference (cm) 84.1 ± 9.3 75.9 ± 9.0‡ 
Hypertension (%) 32.8 29.5 
SBP (mm Hg)
b
 123.1 ± 14.4 117.5 ± 18.5‡ 
DBP (mm Hg)
b
 78.0 ± 9.8 72.8 ± 10.6† 
Triglyceride (mmol/l)
a
 1.34 (1.28-1.41) 1.11 (1.06-1.16)‡ 
HDL cholesterol (mmol/l) 1.24 ± 0.35 1.47 ± 0.36‡ 
LDL cholesterol (mmol/l) 3.28 ± 0.81 3.17 ± 0.82 
Fasting glucose (mmol/l)
a
 5.44 (5.34-5.54) 5.21 (5.11-5.32)† 
2-h glucose (mmol/l)
a
 6.91 (6.66-7.17) 6.93 (6.70-7.17) 
Fasting insulin (mIU/l)
a
 7.30 (6.94-7.68) 7.49 (7.10-7.91) 
HOMA-IR
a
 1.76 (1.67-1.87) 1.74 (1.63-1.85) 
Fibrinogen (g/l) 2.93 ± 0.63 3.05 ± 0.58† 
Adiponectin (mg/l)
a
 5.97 (5.63-6.33) 8.21 (7.79-8.65)‡ 
CRP (mg/l)
a
 0.67 (0.61-0.73) 0.59 (0.54-0.65) 
IL-6 (ng/l)
a
 0.53 (0.49-0.57) 0.48 (0.44-0.52) 
Current smoking (%) 35.1 4.3‡ 
Regular drinking (%) 18.9 3.5‡ 
Data are expressed as meanSD unless otherwise stated.  3 
*P<0.05, †P<0.01, and ‡P<0.001 for men versus women subjects after adjusting for age, 4 
except for age (no adjustment).  5 
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a
Data are expressed as geometric mean (95% CI) due to skewed distributions. 1 
b
Subjects on anti-hypertensive medication were excluded (n=86 in men and 84 in women).     2 
 4 
 
 
Supplementary Table S3  P values for the association of SNPs with hypertension and blood 1 
pressure at baseline in CRISPS-2 2 
SNP P 
 All  Men Women 
Hypertension (n=942) 
rs17147230 0.737 0.574 0.216 
rs1800796 0.432 0.993 0.222 
rs2069837 0.242 0.714 0.145 
    
SBP (n=772)* 
rs17147230 0.736 0.523 0.874 
rs1800796 0.120 0.047 0.618 
rs2069837 0.241 0.064 0.741 
    
DBP (n=772)* 
rs17147230 0.685 0.433 0.671 
rs1800796 0.204 0.271 0.419 
rs2069837 0.186 0.151 0.447 
All P values were adjusted for age and sex (except in sex-specific analysis).  Subjects 3 
homozygous for the minor allele were grouped with heterozygotes for comparison with those 4 
homozygous for the major allele. 5 
*Subjects on anti-hypertensive medication were excluded (n=170).     6 
 7 
8 
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Supplementary Table S4  Baseline characteristics of 415 subjects normotensive at both 1 
CRISPS-2 and CRISPS-3, and 189 subjects hypertensive at both CRISPS-2 and CRISPS-3 2 
Characteristics Normotensive 
(n=415) 
Hypertensive 
(n=189) 
P
c
 
Age (years) 47.0 ± 9.6 57.8 ± 9.6 0.173 
Women (%) 52.3 47.6 0.758 
BMI (kg/m
2
) 23.0 ± 2.9 25.4 ± 3.4 <0.001 
SBP (mm Hg)
a
 112.4 ± 10.2 150.7 ± 13.5 <0.001 
DBP (mm Hg)
a
 71.9 ± 8.1 89.8 ±11.9 <0.001 
IL-6 (ng/l)
b
 0.44 (0.41-0.48) 0.60 (0.54-0.68) 0.005 
men 0.49 (0.44-0.56) 0.56 (0.48-0.67) 0.564 
women 0.40 (0.36-0.46) 0.65 (0.56-0.75) 0.001 
Data are expressed as meanSD or geometric mean (95% CI) unless otherwise stated.  3 
a
Subjects on anti-hypertensive medication were excluded (n=112).     4 
b
Data are expressed as geometric mean (95% CI) due to skewed distributions. 5 
c
Adjusted for baseline age and sex.  6 
 7 
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